30 results match your criteria: "Central West Cancer Care Centre[Affiliation]"
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med
July 2019
From Monash University (I.D.D., M.F., D.W.P.), Eastern Health (I.D.D.), Australian Urology Associates (M.F.), Monash Health (D.W.P.), and the Peter MacCallum Cancer Centre and the University of Melbourne (S.K.S., S.G.W.), Melbourne, VIC, the National Health and Medical Research Council Clinical Trials Centre, University of Sydney (A.J.M., M.R.S., X.C., W.E.H., E.T., S.Y., A.Y.Z.), the Chris O'Brien Lifehouse (M.R.S., L.G.H., A.Y.Z.), the University of Sydney (L.G.H., G.M.), Royal Prince Alfred Hospital (L.G.H.), Kinghorn Cancer Centre, St. Vincent's Hospital, and Garvan Institute of Medical Research (A.M.J.), Macquarie University (A.Y.Z.), and Western Sydney University (R.R.Z.), Sydney, Concord Cancer Centre, Concord Repatriation General Hospital, Concord, NSW (M.R.S.), Port Macquarie Base Hospital and Mid North Coast Cancer Institute Port Macquarie, Port Macquarie, NSW (S.B.), Sydney Adventist Hospital, Wahroonga, NSW (G.M.), the ANZUP Cancer Trials Group, Camperdown, NSW (M.M.), the Adelaide Cancer Centre and the University of Adelaide (F.P.) and the Royal Adelaide Hospital (T.H.T.), Adelaide, SA, and Orange Health Service, Central West Cancer Care Centre, Orange, NSW (R.R.Z.) - all in Australia; BC Cancer and the University of British Columbia, Vancouver (K.N.C.), the Cross Cancer Institute and the University of Alberta, Edmonton (S.A.N.), Canadian Cancer Trials Group, Queen's University (W.P., F.V.-B.), and the Kingston Health Sciences Center (F.V.-B.), Kingston, ON, and the University of Ottawa and the Ottawa Hospital Research Institute, Ottawa (M.N.R.) - all in Canada; Guy's and St. Thomas' NHS Foundation Trust Biomedical Research Centre, Cancer Research UK and King's College London, and Sarah Cannon Research UK, London (S.C.), and the Royal Cornwall Hospital, Truro (A. Thomson) - all in the United Kingdom; Auckland City Hospital, Auckland (N.J.L.), and the Waikato District Health Board, Hamilton (A. Tan) - both in New Zealand; Cancer Trials Ireland (J.M., R.M.), Mater Misericordiae University Hospital (J.M.), and St. Vincent's University Hospital and University College Dublin (R.M.D.) - all in Dublin; and Dana-Farber Cancer Institute and Harvard Medical School (C.J.S.) - both in Boston.
Background: Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, with or without early docetaxel, will improve survival in men with metastatic, hormone-sensitive prostate cancer.
Methods: In this open-label, randomized, phase 3 trial, we assigned patients to receive testosterone suppression plus either open-label enzalutamide or a standard nonsteroidal antiandrogen therapy (standard-care group).
Patterns of immunotherapy use and management of toxicities in regional and tertiary settings.
Intern Med J
August 2019
Central West Cancer Care Centre, Orange Health Service, Sydney, New South Wales, Australia.
Article Synopsis
- The introduction of immune checkpoint inhibitors CTLA-4 and PD-1 has led to their widespread use in treating metastatic melanomas, renal cell carcinomas, and non-small-cell lung cancers, including in regional areas.
- Despite their generally better toxicity profiles than chemotherapy, these immunotherapies can cause serious immune-related adverse effects (irAE).
- In a study comparing regional and tertiary oncology services, usage rates of immunotherapy were found to be similar, with regional services identifying and treating irAE more promptly, leading to decreased need for intensive management.
Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).
BMJ Open
September 2018
NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
Article Synopsis
- Chemotherapy-induced nausea and vomiting (CINV) continues to be a significant problem for patients despite standardized antiemetic treatments, prompting research into the effectiveness of cannabinoid-based therapies like THC and CBD for relief.
- The CannabisCINV study aims to evaluate the efficacy, safety, and cost-effectiveness of a THC/CBD extract (TN-TC11M) as an additional treatment for CINV in patients receiving chemotherapy who still experience nausea despite existing therapies.
- In this multicenter pilot study, 80 adult patients will participate in a randomized crossover design using either the cannabinoid extract or a placebo, with various endpoints focused on patient response, quality of life, and healthcare resource utilization.
Consensus minimum data set for lung cancer multidisciplinary teams: Results of a Delphi process.
Respirology
October 2018
University of Sydney, Sydney Catalyst Translational Cancer Research Centre, Sydney, NSW, Australia.
Background And Objective: While multidisciplinary team (MDT) care in lung cancer is widely practiced, there are few guidelines for MDT on best data collection strategies. MDT meetings need ready access to information for the provision of optimal treatment recommendations (the primary purpose of the meeting), audit of team performance and benchmarking. This study aimed to develop a practical data set designed for these goals through a recognized consensus process with health professionals who participate in formal MDT settings.
View Article and Find Full Text PDFPseudoprogression Associated with Clinical Deterioration and Worsening Quality of Life in Malignant Pleural Mesothelioma.
J Thorac Oncol
January 2018
University of Sydney, Camperdown, New South Wales, Australia; Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.